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Multiple medical and surgical options have been de-scribed for the treatment of congenital hydroceph-
alus in dogs. Surgical treatment typically consists of 
VPS placement. However, this procedure can be associ-
ated with complications and implant failure.1–8 A recent 
study2 reported clinical improvement in 26 of 36 (72%) 
surgically treated animals (dogs and cats). However, 8 
(22%) animals developed postoperative complications 
and 13 (36%) died or were euthanized as a result of 
hydrocephalus.2 Similar complication rates have been 
reported in smaller studies1,3 following VPS placement 
for treatment of hydrocephalus in dogs.
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OBJECTIVE
To evaluate signalment, clinical findings, and outcomes of dogs with congen-
ital hydrocephalus treated medically with orally administered prednisolone 
or surgically by ventriculoperitoneal shunt placement.
DESIGN
Retrospective case series.
ANIMALS
40 client-owned dogs.
PROCEDURES
Medical records from 2005 to 2016 were searched to identify dogs with 
congenital hydrocephalus confirmed by MRI examination. Patients were 
categorized by treatment (medical vs surgical). Signalment, clinical signs, 
neurologic examination findings, results of diagnostic tests, duration of hos-
pitalization, complications potentially related to treatment, and follow-up 
information were recorded. Outcome was categorized on the basis of clini-
cal (neurologic) signs as improved, stabilized, or deteriorated. Variables of 
interest were compared between groups by Fisher exact or Mann-Whitney 
U tests.
RESULTS
28 and 12 dogs had surgical and medical treatment, respectively; 3 medically 
treated dogs subsequently underwent ventriculoperitoneal shunt place-
ment. No significant differences were noted in clinical or imaging findings 
between surgically and medically treated dogs. Median follow-up time was 
9 months and 15.5 months for medically and surgically treated dogs, re-
spectively. Of 12 medically treated dogs, 6 improved and 6 deteriorated. Of 
26 surgically treated dogs with data available, 14 (54%) improved, 1 (4%) 
stabilized, and 11 (42%) deteriorated; 4 (15%) had known postoperative 
complications.
CONCLUSIONS AND CLINICAL RELEVANCE
Approximately half of the dogs treated with prednisolone in this population 
had neurologic improvement at last follow-up; results of surgical treatment 
were comparable to those in previous studies. Further research is needed 
to assess factors associated with acceptable outcomes for dogs with con-
genital hydrocephalus. ( J Am Vet Med Assoc 2019;254:835–842)
The goal of medical management for this condi-
tion is to decrease CSF production or increase CSF 
absorption. A variety of medications, including gluco-
corticoids,5 have been suggested for decreasing CSF 
production. Although the exact mechanism of action 
of glucocorticoids in terms of their effects on CSF are 
not completely understood, results of experimental 
studies in rabbits7 as well as dogs8 have revealed de-
creases in CSF production following administration 
of these drugs. However, to the best of the authors’ 
knowledge, no previous veterinary studies have evalu-
ated the clinical variables and outcomes of dogs treat-
ed with corticosteroids for congenital hydrocephalus, 
and this type of treatment is generally considered to 
achieve only temporary alleviation of clinical signs. 
Other drugs that have been investigated as a means to 
decrease CSF production include furosemide (a loop 
ABBREVIATIONS
VBHR  Ventricle-to-brain height ratio
VPS  Ventriculoperitoneal shunt
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diuretic), acetazolamide (a carbon anhydrase inhibi-
tor), and omeprazole (a proton pump inhibitor).9–12
The aim of the study reported here was to iden-
tify the clinical findings and outcomes of dogs with 
congenital hydrocephalus treated medically with 
oral prednisolone administration or surgically with 
VPS placement. We hypothesized that no differences 
would exist in clinical findings between dogs treated 
medically and surgically, and that surgical manage-
ment would result in better response to treatment 
and outcome than medical management.
Materials and Methods
The retrospective study was approved by the 
Royal Veterinary College Ethics and Welfare Commit-
tee (protocol number URN 2015 1425). The survey 
used to obtain follow-up information was created by 
the authors (SD and ZG) and was reviewed and ap-
proved by the same committee.
Case selection criteria
Hard-copy and electronic medical records of 
the University of London Royal Veterinary College 
Small Animal Referral Hospital from January 1, 2005, 
through October 1, 2016, were reviewed to identify 
dogs that had a diagnosis of congenital hydrocephalus 
made on the basis of findings consistent with the diag-
nosis on MRI evaluation,13 full neurologic examination 
by a board-certified veterinary neurologist, and clini-
cal signs compatible with the disease. Keywords for 
electronic records searches included “hydrocephalus,” 
“congenital hydrocephalus,” and “ventriculoperito-
neal shunt.” Dogs were included in the study if the 
complete medical record and diagnostic images were 
available for review. For study purposes, records were 
considered complete if the following information 
was available: signalment (including body weight at 
the time of evaluation), history, signs for which the 
patient was initially examined, duration of signs prior 
to evaluation, age at onset of clinical signs, treatment 
prior to evaluation at the study hospital and response 
to prior treatment (if applicable), physical and neuro-
logic examination findings on initial evaluation, re-
sults of diagnostic imaging, treatment received, and 
duration of stay at the study hospital.
All diagnostic images and medical record files 
were reviewed by a board-certified veterinary neu-
rologist (SD) to evaluate diagnostic information and 
study eligibility. Dogs were excluded if the medical 
files or imaging records were not available or if other 
abnormalities were detected that could have caused 
or contributed to the dog’s clinical signs.
Medical records review
Data collected for each dog included signalment, 
duration and type of clinical signs, and neurologic ex-
amination findings. Diagnostic tests performed and 
their results, treatments received (medical or surgical 
and any postoperative medications), reported com-
plications, and duration of hospitalization were also 
recorded. Dogs were categorized for study purposes 
as being treated medically or surgically.
Procedures
Imaging—Diagnostic MRI was performed prior 
to referral or at the time of admission with dogs un-
der general anesthesia. When MRI was performed at 
the study hospital, a 1.5T unita was used. Dogs were 
placed in dorsal recumbency for scanning; protocols 
included a minimum of T2-weighted and T1-weighted 
sagittal and transverse images, fluid-attenuated inver-
sion recovery, and T1-weighted transverse images 
after administration of gadolinium-based contrast 
mediumb (0.5 mL/kg [0.23 mL/lb], IV). Owners were 
informed of treatment options by a veterinary neurol-
ogy specialist or specialist in training. The treatment 
undertaken was determined on the basis of owner 
preference.
The MRI images were retrospectively examined 
by 1 investigator (SG), and the cerebral VBHR ([ce-
rebral ventricle height/brain height] X 100) was cal-
culated as previously described.14 The T1-weighted 
images were assessed at the level of the interthalamic 
adhesion. A mean VBHR was calculated for each dog 
from values calculated for the left and right ventricles. 
These values were used in intergroup comparisons.
Surgical treatment—Dogs were premedicated 
with methadone (0.2 mg/kg [0.09 mg/lb], IV), and 
anesthesia was induced with propofol (4 mg/kg [1.8 
mg/lb], IV). Following endotracheal intubation, gen-
eral anesthesia was maintained with isoflurane in 
oxygen. Placement of a unilateral VPS was performed 
as previously described.1 Dogs were positioned in 
partial sternal recumbency (head and shoulders) and 
partial right lateral recumbency (pelvis). The shunt 
was placed into the ventricle of the brain that was 
considered to be most dilated on examination of the 
diagnostic images. A commercial shunt systemc with 
an ultra-small, low-low or medium pressure valve 
(opening pressures of 1 and 8.5 cm H2O, respective-
ly) was used in all dogs. A rostrotentorial craniotomy 
approach was used with a burr hole created in the 
parietal bone over the selected region by means of a 
pneumatic drill.d An incision was made into the dura 
mater, and the ventricular catheter was introduced 
through the cerebral cortex via a stylet. An anchor 
was fitted into the burr hole and sutured to the perios-
teum or temporalis muscle fascia. Following incision 
and dissection of the flank region skin, muscle layers, 
and peritoneum, the distal catheter was inserted into 
the abdominal cavity and secured in place with poly-
propylene suture in a finger-trap suture pattern. The 
free end of the distal catheter was passed through a 
subcutaneous tunnel to the cervical region, where it 
was attached to the one-way valve. All incisions were 
routinely closed in 3 layers over the shunt. Postop-
erative analgesic treatment was provided with metha-
done (0.1 to 0.2 mg/kg [0.05 to 0.09 mg/lb], IV, q 4 
h) and paracetamol (10 mg/kg [4.5 mg/lb], PO, q 12 
h). After surgery, all dogs received a tapering dose of 
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prednisolone (beginning with 0.2 to 0.5 mg/kg, PO, 
q 12 to 24 h). An antiepileptic medication (pheno-
barbitone, 2 to 3 mg/kg [0.9 to 1.4 mg/lb], PO, q 12 
h) was also administered if the patient had a history 
of seizures. Prednisolone treatment was typically 
discontinued for surgical patients 9 to 14 days after 
surgery.
Medical treatment—Patients that were treated by 
medical management alone received prednisolone 
at an initial dose of 0.5 to 1 mg/kg (0.23 to 0.45 mg/
lb, PO, q 12 to 24 h), tapering down to a minimally 
effective dose or discontinued if possible. Antiepi-
leptic medication (phenobarbitone, 2 to 3 mg/kg, 
PO, q 12 h) was added if the patient had a history 
of seizures.
Follow-up—Short-term follow-up information was 
obtained from the medical records of reexamination 
at the Royal Veterinary College Small Animal Referral 
Hospital 2 to 6 weeks after VPS placement (surgical 
treatment group) or after starting oral prednisolone 
treatment (medical treatment group). Recent history 
and neurologic signs were recorded and compared 
with the data obtained on initial examination.
Complete follow-up (including long-term follow-
up, if applicable) and outcome information was ob-
tained from a combination of telephone interviews 
with referring veterinarians and owners. Referring 
veterinarians were first contacted and asked a series 
of questions regarding the patient’s clinical status, 
current medications, neurologic deficits present, and 
progression after commencement of treatment. If the 
dog had died, the date, cause of death (if known), 
and last recorded neurologic status were recorded. 
Conforming to local ethics and welfare guidelines, 
the owners of dogs known to have died were not 
contacted further. Owners of dogs last known to be 
alive were mailed a letter that included the study de-
tails and a standardized questionnaire developed by 
the authors (Supplementary Appendix S1, avail-
able at avmajournals.avma.org/doi/suppl/10.2460/
javma.254.7.835). At this stage, owners were given 
the opportunity to opt out of being contacted fur-
ther. Questionnaires were subsequently completed 
by owners who elected to participate via telephone 
interview with 1 investigator (ZG). Treatment out-
come was determined from the data acquired from 
both referring veterinarians and owners; dogs were 
categorized as improved, stabilized, or deteriorated 
on the basis of change in the original clinical (neu-
rologic) signs. Dogs that initially showed signs of im-
provement or stabilization but subsequently had clin-
ical deterioration were categorized as deteriorated at 
long-term follow-up.
Statistical analysis
Statistical analysis was performed with a commer-
cial software package.e Data were assessed for nor-
mality with the Shapiro-Wilk test. Fisher exact tests 
were used to investigate differences in sex, presence 
of various neurologic signs, short-term outcome, and 
long-term outcome between groups. Mann-Whitney U 
tests were used to investigate intergroup differences 
in age at diagnosis, VBHR, body weight, and duration 
of clinical signs at diagnosis. For all comparisons, val-
ues of P < 0.05 were considered significant.
Results
The records search identified 52 dogs with con-
genital hydrocephalus. Of these, 5 were excluded ow-
ing to incomplete medical records or imaging files; 
another 7 were excluded because they were eutha-
nized without treatment owing to financial concerns 
and uncertainty about long-term outcome and qual-
ity of life. Forty dogs with congenital hydrocephalus 
were enrolled in the study; 28 and 12 underwent 
surgical and medical management, respectively. One 
dog treated medically received prednisolone PO for 4 
days prior to referral; the treatment start date for this 
patient was recorded from the day on which steroids 
were first administered. No other patients received 
medical treatment for the condition prior to referral. 
Three medically treated dogs subsequently under-
went VPS placement because they had an unsatisfac-
tory response to medical management; these 3 dogs 
were not included in the surgical group for descrip-
tion and statistical analysis. Five dogs underwent MRI 
prior to the referral examination, and 35 had the pro-
cedure performed on admission to the study hospital.
The most commonly represented breeds were 
English Bulldog (n = 5), Chihuahua (4), and Pug (3). 
Other breeds included Maltese, Border Collie, Dachs-
hund, and Lhasa Apso (2 of each), as well as French 
Bulldog, Cavalier King Charles Spaniel, English 
Cocker Spaniel, Shetland Sheepdog, Papillion, Akita, 
Great Pyrenees, Golden Retriever, Labrador Retriev-
er, Samoyed, Gordon Setter, Boxer, Yorkshire Terrier, 
and Jack Russell Terrier (1 of each). There were 6 
mixed-breed dogs. Of the 40 dogs, 19 were females 
(8 spayed and 11 sexually intact) and 21 were males 
(7 neutered and 14 sexually intact). The median age 
of all dogs was 12 months (range, 2 to 123 months) 
and median weight was 6.5 kg (14.3 lb; range, 1.1 to 
34 kg [2.4 to 75.0 lb]).
The median duration of clinical signs before di-
agnosis was 1.6 months (range, 1 day to 57 months). 
Thirty-seven of 40 (93%) dogs had neurologic abnor-
malities on initial examination. The remaining 3 dogs 
had a history of seizures without abnormalities de-
tected during neurologic examination. Observed neu-
rologic abnormalities included proprioceptive deficits 
(n = 27); inappropriate mentation (22); absent menace 
response unilaterally (4) or bilaterally (21); vestibular 
(9), proprioceptive (7) or cerebellar (2) ataxia; and 
circling (8). Bilateral ventrolateral strabismus was ob-
served in 5 dogs, and 7 dogs had a head tilt. A dome-
shaped head was noted for 8 dogs. Generalized tonic-
clonic seizures were reported for 14 dogs, and focal 
seizures were reported for 1 dog. On MRI, the median 
cerebral VBHR was 43.22% (range, 20.93% to 92.96%).
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Twenty-two dogs had CSF analysis performed 
(16 and 6 in the surgical and medical treatment 
groups, respectively). For surgically treated dogs, 
the median total nucleated cell count was 2.5 cells/
µL (range, 0 to 152 cells/µL; reference range, < 5 
cells/µL), and the median CSF protein concentration 
was 16.5 mg/dL (range, 5 to 3,000 mg/dL; reference 
range, < 25 mg/dL). For medically treated dogs, the 
median total nucleated cell count was 2.5 cells/µL 
(range, 0 to 8 cells/µL) and median CSF protein con-
centration was 13.5 mg/dL (range, 11 to 23 mg/dL). 
Six dogs in the surgical treatment group and 1 in 
the medical treatment group had total nucleated cell 
counts or CSF protein concentrations greater than 
the upper limit of the respective reference range. 
Three dogs (all treated surgically) had both of these 
findings.
No significant differences were observed be-
tween medically and surgically treated dogs for age, 
body weight, sex, duration and type of clinical signs, 
presence and type of neurologic deficits, seizure his-
tory, or VBHR measured on MRI (Table 1). Owner 
questionnaires were completed by 12 individuals (5 
and 7 owners of dogs that had medical and surgical 
treatment, respectively).
Short-term follow-up
Medically treated dogs—Ten of the 12 medically 
treated dogs had short-term follow-up visits record-
ed. Six of the 10 dogs were classified as neurologi-
cally improved, 1 was classified as deteriorated, and 
3 were classified as stabilized at the time of the last 
short-term follow up visit. The 3 dogs that initially 
had medical treatment and subsequently underwent 
VPS placement had the surgery performed 3.5 weeks, 
2.5 months, and 3.8 months after medical treatment 
was initiated. The procedure was successfully com-
pleted in all 3 dogs, and the dogs continued to im-
prove neurologically after hospital discharge.
Surgically treated dogs—Surgical placement of a 
VPS was uneventful in all 28 dogs, and the median 
duration of hospitalization was 3 days (range, 1 to 
13 days) after surgery. Two dogs had seroma forma-
tion over the calvarial surgical site in the immediate 
postoperative period. Twenty-five of the 28 dogs had 
short-term follow-up visits. At the time of the last 
short-term follow-up visit, 20 of 25 (80%) dogs had 
improved, 3 (12%) had deteriorated, and 2 (8%) had 
stabilized. All 3 dogs that had deteriorated despite 
surgery were euthanized between 2 and 3 weeks af-
ter surgery without further diagnostic investigations.
Intergroup comparisons—The described propor-
tions of dogs in the medical and surgical treatment 
groups that were categorized as improved, stabilized, 
or deteriorated at the last short-term follow-up visit 
were compared. These proportions did not differ sig-
nificantly between groups (P = 0.393, P = 0.128, and 
P = 1.0, respectively).
Outcomes
Medically treated dogs—None of the 12 medically 
treated dogs were lost to follow-up. The median fol-
low-up time was 9 months (range, 3.5 weeks to 71.7 
months) after the start of medical treatment. Six dogs 
in the medical treatment group were categorized as 
improved, compared with their pretreatment neuro-
logic condition, and 3 of the 6 were reported to be 
neurologically normal at the time of last follow-up. 
Five of these 6 dogs were still alive at last follow-up 
(median follow-up time, 67.4 months; range, 56 to 
71.7 months). One dog died 10 months after starting 
treatment for reasons unrelated to hydrocephalus or 
its medical management. Four of the 6 dogs that were 
  Surgically treated dogs Medically treated dogs 
Variable (n = 28) (n = 12) P value
Age (mo) 9.5 (2–123) 17 (4–88) 0.247
Body weight (kg) 6 (1.1–34) 10 (2.7–33) 0.066
Sex   0.494
 Male 16 (57) 5 (42) 
 Female 12 (43) 7 (58) 
Duration of clinical signs (mo) 1 (0.03–57) 3.6 (0.2–19.7) 0.900
Seizure history 10 (36) 5 (42) 0.736
Neurologic abnormalities on examination 27 (96) 10 (83) 0.209
  Inappropriate mentation 16 (57) 6 (50) 1.0
  Ventrolateral strabismus 3 (11) 2 (17) 0.672
  Absent menace response 19 (68) 6 (50) 0.311
  Proprioceptive deficits 21 (75) 6 (50) 0.154
  Ataxia 13 (46) 5 (42) 1.0
  Cervical hyperesthesia 8 (29) 3 (25) 1.0
  Circling behavior 6 (21) 2 (17) 1.0
  Head tilt 4 (14) 3 (25) 0.410
Dome-shaped head 5 (18) 3 (25) 0.677
VBHR (%) 48.57 (20.93–92.96) 38.29 (25.40–88.36) 0.114
Values are number (%) or median (range). Values of P < 0.05 were considered significant.
Table 1—Signalment, clinical data, and diagnostic imaging findings of interest at the time of initial examination for 40 dogs in a 
retrospective study to evaluate clinical findings and outcomes of dogs with congenital hydrocephalus treated medically with orally 
administered prednisolone or surgically by VPS placement.
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reported to be neurologically normal at the time of 
last follow-up had been weaned off of prednisolone 
completely; the median duration of treatment for 
these dogs was 12 months (range, 9 to 15 months). 
The remaining 6 dogs had deteriorated despite medi-
cal treatment. Three of these dogs were euthanized 1.7 
months, 2.9 months, and 8 months after treatment was 
initiated. The other 3 were the dogs that subsequently 
underwent VPS placement because of deterioration 
with medical management. One of these dogs experi-
enced shunt migration and occlusion 8.9 months after 
surgery and was subsequently euthanized; the other 
2 died 1 year and 2.5 years after surgery for reasons 
unrelated to hydrocephalus or VPS placement.
All of the 5 medically treated dogs that had a his-
tory of seizures at the start of treatment were still re-
ceiving antiepileptic medication (phenobarbitone, 2 
to 3 mg/kg [0.91 to 1.36 mg/lb], PO, q 12 h) at the 
time of last follow-up. Two dogs had continued to 
have seizures at rates similar to those reported prior 
to treatment; these were the dogs that were eutha-
nized 1.7 months and 8 months after treatment start-
ed. The cause for euthanasia of 1 dog was aggression 
and incontinence, and that for the other dog was the 
lack of improvement in seizure frequency. One other 
dog had an increase in seizure frequency and was 
euthanized because of status epilepticus 2.9 months 
after treatment started. The remaining 2 of 5 dogs 
had reduced seizure frequency, and both were alive 
at last follow-up (56 and 67.4 months after treatment 
was initiated).
Surgically treated dogs—Two of the 28 surgically 
treated dogs were lost to long-term follow-up. The 
median duration of complete follow-up for the re-
maining 26 dogs was 15.5 months (range, 2 weeks to 
70.8 months) after surgery.
Fourteen of 26 (54%) dogs with follow-up avail-
able had improved, compared with their pretreat-
ment neurologic condition, and 9 of these 14 were 
reported to be neurologically normal at last follow-
up. All 14 dogs were still alive at last follow-up (me-
dian follow-up time, 33.3 months; range, 1.9 to 70.8 
months). Eleven of 26 (42%) dogs had deteriorated 
despite surgical intervention, and 1 (4%) had stabi-
lized. Of the 11 dogs classified as deteriorated, 5 were 
perceived to have initial improvement or stabilization 
of neurologic signs prior to a sudden deterioration 
that was observed a median of 27.3 months (range, 
5 to 46.7 months) after surgery. Ten of these 11 dogs 
were euthanized at a median of 4.9 months (range, 
2 weeks to 50 months) after surgery. The dog that 
was classified as stabilized was alive at last follow-up 
(52 months) and continued to experience cluster sei-
zures at a frequency similar to that reported prior to 
surgery.
All 10 nonsurviving dogs were euthanized as a 
presumed direct consequence of the condition or 
complications related to treatment. Three of these 
were the dogs euthanized in the short-term follow-up 
period because of neurologic deterioration. Six other 
dogs were euthanized because of neurologic deterio-
ration (n = 3), increase in seizure frequency (1), oc-
currence of status epilepticus (1), or cluster seizures 
(1) between 2.5 and 50 months after surgery; no fur-
ther diagnostic tests were performed to determine 
the cause of deterioration. One dog was euthanized 
because of a complication after VPS placement; over-
shunting led to collapse of a lateral ventricle and sub-
dural hemorrhage 5 months after surgery.
Another 3 dogs in this group were known to 
have complications directly related to VPS place-
ment. These included catheter migration and block-
age (1.6 months after surgery), shunt exteriorization 
(8 months after surgery), and kinking of the catheter 
in the peritoneum (5.3 months after surgery). All of 
these dogs underwent successful revision surgery 
and were alive at last follow-up.
Of 10 surgically treated dogs that had a history 
of seizures, 1 was lost to long-term follow-up. Two of 
the remaining dogs were reported to have reduced 
seizure frequency at last follow-up, compared with 
that prior to VPS placement, and 4 continued to have 
seizures at rates similar to those before surgery. The 
other 3 dogs had been euthanized because of seizure 
activity as previously described.
Intergroup comparisons—The reported propor-
tions of dogs in the medical and surgical treatment 
groups that were categorized as improved, stabilized, 
or deteriorated at the time of last follow-up (or the 
time the treatment approach was changed [for the 3 
medically treated dogs that later had surgery]) were 
analyzed. These values did not differ significantly (P 
= 1.0, P = 1.0, and P = 0.734, respectively) between 
groups.
Discussion
Although VPS placement is considered the treat-
ment of choice for dogs with congenital hydrocepha-
lus, it is associated with well-known complications 
and potential failure. To the authors’ knowledge, no 
previous veterinary studies have evaluated the out-
come of dogs treated with corticosteroids for con-
genital hydrocephalus. Overall, we did not detect any 
significant differences in selected signalment vari-
ables, duration of clinical signs, presence and type of 
neurologic deficits, seizure history or cerebral VBHR 
on diagnostic MRI images between surgically and 
medically treated dogs with congenital hydrocepha-
lus. It remains unclear which clinical characteristics 
currently influence owners and clinicians to prefer 
or recommend one treatment option over the other. 
Given the small numbers of patients included in the 
study, these findings should be interpreted with cau-
tion. However, approximately half of the dogs in 
both groups had good long-term outcomes; 6 of 12 
medically treated dogs were considered neurologi-
cally improved and 5 were still alive at last follow-
up, whereas 14 of 26 surgically treated dogs were 
described as neurologically improved and 15 (includ-
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ing 1 considered neurologically stabilized) were still 
alive at last follow-up. Although this study failed to 
provide evidence of superiority for surgical or medi-
cal management, our results suggested that medical 
management can be associated with a positive out-
come in selected cases.
In an effort to select as homogenous a patient 
population as possible, only dogs with a confirmed 
diagnosis of congenital hydrocephalus following MRI 
and examination by a board-certified veterinary neu-
rologist were included in the study. The breeds, ages, 
and clinical signs of affected dogs in this study were 
similar to those reported previously.1,3,15,16
Seven dogs with congenital hydrocephalus were 
euthanized after a diagnosis was reached without 
treatment attempted. Financial concerns and un-
certainty about long-term outcome were the factors 
leading to this decision in each case. It could not be 
excluded that the owners of these dogs would have 
considered another decision if they would have been 
aware of the potential response to glucocorticoid 
administration. This confirmed the need for further 
studies evaluating the outcome of nonsurgical treat-
ment for dogs with congenital hydrocephalus. Al-
though the findings of this small study may not be 
completely representative of the larger population of 
dogs with this condition, it is hoped that the results 
can provide practitioners with additional information 
to help advise dog owners more completely about 
available treatment options and outcomes for dogs 
with congenital hydrocephalus.
The finding that 6 of 12 medically treated dogs 
had neurologic improvement on long-term follow-up, 
with 5 dogs still alive at this time (all ≥ 4.5 years after 
treatment started) and 4 dogs having been tapered 
off of prednisolone completely, suggested that neuro-
logic status of some dogs with congenital hydroceph-
alus can improve or stabilize for a substantial period 
of time with corticosteroid treatment. The effects of 
glucocorticoids on CSF production and absorption 
remain incompletely understood. Their use is gener-
ally recommended to stabilize clinical signs until VPS 
placement is performed or as alternative treatment 
when surgery is not feasible.5,17 The goal of medi-
cal treatment is to decrease CSF production, lower 
CSF volume, and reduce tissue destruction.18 Results 
of experimental studies7,8 in rabbits and dogs have 
shown reduced CSF production following short-term 
and prolonged administration of glucocorticoids. Five 
days of treatment with betamethasone reduced CSF 
production by 43% in healthy rabbits, and a rapid de-
crease in CSF production was found in healthy dogs 
≤ 1 hour after IV dexamethasone administration.7,8 It 
has been proposed that glucocorticoids exert this ef-
fect through reduction of choroid plexus transport 
capacity and of sodium-potassium ATPase activity.7 
In addition, these drugs may reduce periventricular 
edema if it is present.13
In human patients, chronic hydrocephalus can 
sometimes develop beginning in infancy but arrest 
without evidence of neurologic deterioration. This 
condition has been described as arrested hydroceph-
alus, previously untreated congenital hydrocephalus, 
compensated hydrocephalus, long-standing overt 
ventriculomegaly of adults, or a syndrome of hydro-
cephalus in young and middle-aged adults.19,20 Con-
sensus on the treatment of that condition is lacking, 
and some clinicians advocate a conservative approach 
with serial reassessment.21,22 However, more recent 
evidence has suggested that the condition leads to a 
slow and continuous neurologic decline in most pa-
tients, and this has resulted in recommendations for 
prompt surgical intervention at the time of diagno-
sis.20,23–25 It is unknown whether a similar condition 
exists in dogs; however, a slow neurologic decline 
might be more difficult to observe in such patients.
In laboratory settings, omeprazole significantly 
reduced CSF production (by 26% to 50%) following 
ventriculocisternal or IV administration in studies 
of healthy dogs and rabbits.9,10 However, a recent pi-
lot study26 of 15 healthy Beagles found that a 2-week 
course of oral omeprazole treatment had no signifi-
cant effect on CSF production. Similarly, oral admin-
istration of acetazolamide for 3 weeks (1 dog) or 6 
weeks (6 dogs) did not improve clinical signs or re-
duce ventricular volume in clinical patients with con-
genital hydrocephalus.27,28
In the present study, 20 of 25 (80%) dogs that under-
went VPS placement (excluding dogs that had sur-
gery after failure of medical management) and were 
seen for follow-up visits had neurologic improvement 
between 2 and 6 weeks after surgery. These results 
were comparable to previous veterinary studies1,3 in 
which neurologic improvement was detected in 13 of 
14 dogs and 8 of 12 dogs at recheck visits between 2 
and 4 weeks after surgery. Similarly, in a recent study 
comprising 36 cases of congenital hydrocephalus in 
dogs and cats, 26 (72%) animals had improvement in 
clinical signs at a median follow-up time of 6 months 
after surgery.2 In the present study, 14 of 26 (54%) 
dogs with long-term follow-up information available 
had neurologic improvement at the time of final data 
capture (median, 15.5 months after surgery) and 11 
(42%) had deterioration, including 5 that were re-
ported to be doing well prior to a sudden decline. 
Unfortunately, many of these dogs did not undergo 
further diagnostic investigations, and the exact cause 
of neurologic deterioration was unknown.
The complication rate after hospital discharge for 
dogs that underwent VPS treatment and had the in-
formation available (4/26 [15%]) in the present study 
was comparable to rates of 8 of 36 (22%) and 4 of 
14 found in other retrospective veterinary case series 
that included dogs with hydrocephalus2,3; it should 
be noted that 1 of another 3 dogs in our study that 
underwent VPS placement after clinical deterioration 
during medical management also had shunt-related 
complications. In agreement with a previous study,2 
complications most commonly developed in the early 
postoperative period, and all occurred < 9 months 
after surgery in the present study. Complications fol-
lowing VPS placement can include infection, signs of 
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pain, and overshunting leading to ventricular collapse 
and subdural hematoma formation. Undershunting can 
occur with catheter occlusion, kinking, disconnec-
tion, or shunt migration.1–3,5,6 The complication rate 
in the present study was possibly underestimated, 
given that multiple dogs were euthanized following 
neurologic deterioration without further diagnostic 
testing. Overall, 10 of 26 (38%) surgically treated 
dogs with known outcomes were euthanized be-
cause of unresolved clinical signs or complications 
associated with VPS placement. Similar results have 
been reported1,2 previously, with euthanasia of 3 of 
12 dogs and 13 of 36 (36%) dogs and cats with con-
genital hydrocephalus. In a multicenter study29 of 
344 hydrocephalic children that had 1 of 3 VPS valve 
types placed, shunt failure rates requiring additional 
surgery were approximately 40% at 1 year after im-
plantation, regardless of shunt design. It is important 
that owners are aware of the prevalence of shunt-
related complications and the potential for a lack of 
improvement after shunt placement, which might ne-
cessitate additional diagnostic investigations and revi-
sion surgery in the future.
Of 9 surgically treated dogs that had a history 
of seizures and had outcome data available, only 2 
had reduced seizure frequency after surgery in the 
present study. Three of the remaining 7 were eutha-
nized because of increased seizure frequency or oc-
currence of status epilepticus. The number of such 
dogs in our study was too small for conclusions to 
be drawn; however, this finding was in agreement 
with observations in another small study.3 Further 
research is needed to determine whether VPS place-
ment is truly ineffective for reducing seizure frequen-
cy in dogs with congenital hydrocephalus.
The present study was limited by the small num-
ber of dogs and by its retrospective nature, which ne-
cessitated reliance on medical records accuracy, and 
did not allow for standardized treatment or follow-up 
assessment for all dogs. Although no significant differ-
ences were detected between the medically and sur-
gically treated groups in terms of the investigated sig-
nalment (age, weight, and sex), clinical (duration of 
clinical signs, presence of neurologic abnormalities, 
and seizure history) and imaging (VBHR) variables, 
comparisons between the 2 groups were likely influ-
enced by the lack of random treatment assignment 
as well as the small numbers of dogs available for in-
clusion and high degree of interindividual variability 
for most measures. Although follow-up data were col-
lected from a combination of referring veterinarian 
interviews and owner questionnaires, it was possible 
that owner recall bias influenced the outcome results 
in some cases. Furthermore, not all medically treated 
dogs had CSF analysis performed owing to concerns 
of high intracranial pressure suggested by MRI find-
ings, and it could not be completely excluded that 
some of the medically treated dogs had inflammatory 
CNS disease (eg, meningoencephalitis of unknown 
etiopathogenesis). It is unknown whether neurologic 
signs would have stabilized in some patients regard-
less of treatment, and further studies are warranted 
to evaluate the natural progression of congenital hy-
drocephalus and investigate potential prognostic fac-
tors for successful medical and surgical treatment.
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Footnotes
a. Intera 1.5T, Philips Medical Systems, Eindhoven, Netherlands.
b. Gadiovist 1.0 mmol/mL solution for injection, Bayer, Berlin, 
Germany.
c. PS Medical CSF-Flow Control, Medtronic, Minneapolis, Minn.
d. Hall Surgairtome II, Hall, Largo, Fla.
e. IBM SPSS Statistics for Windows, version 23.0, IBM Corp, 
Armonk, NY.
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From this month’s AJVR 
Development and assessment of a novel precordial lead system  
for accurate detection of right atrial and ventricular depolarization  
in dogs with various thoracic conformations
Roberto A. Santilli et al
OBJECTIVE
To assess recording accuracy of right atrial and ventricular depolarization during 12-lead ECG 
when precordial lead V1 was positioned at each of 5 locations on the thorax of dogs with various 
thoracic conformations.
ANIMALS
60 healthy client-owned dogs.
PROCEDURES
20 dogs were allocated to each of 3 groups (brachymorphic, mesomorphic, or dolichomorphic) on 
the basis of thoracic conformation. Each dog remained unsedated and was positioned in right lateral 
recumbency for a series of five 12-lead surface ECGs, with V1 located adjacent to the sternum in the 
fifth intercostal space (ICS; control), at the costochondral junction (CCJ) of the right first ICS (1st-R), 
at the CCJ of the right third ICS, at the right third ICS where the thorax was the widest, and at the 
CCJ of the left first ICS. Electrocardiographic variables were compared among the 5 ECG tracings.
RESULTS
When V1 was at the control location, the P wave was positive for all dogs; however, consistent 
recording of right atrial and ventricular depolarization (ie, R wave-to-S wave ratio [R/S] < 1) 
occurred more frequently for brachymorphic dogs (16/20) than for dolichomorphic (7/20) and 
mesomorphic (6/20) dogs. When V1 was at the 1st-R location, the P wave was negative for most 
dogs, and R/S was < 1 for the majority of dogs in the brachymorphic (19/20), mesomorphic 
(17/20), and dolichomorphic (16/20) groups. The median R/S for V1 at the 1st-R location was 
significantly lower than that for the other 4 V1 locations.
CONCLUSIONS AND CLINICAL RELEVANCE
Results indicated that placement of V1 at the 1st-R location provided correct evaluation of right 
atrial and ventricular depolarization in most dogs regardless of thoracic conformation. (Am J Vet 
Res 2019;80:358–368)
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